Cancer immunotherapy has been firmly established as a new milestone for cancer therapy,
with the development of multiple immune cells as therapeutic tools. Natural killer (NK) cells …

Natural killer (NK) cells can induce an antigen-independent immune response against
malignant cells. A growing number of scientific reports and clinical studies have shown …

Patients with acute myeloid leukaemia (AML) often achieve remission after therapy, but
subsequently die of relapse that is driven by chemotherapy-resistant leukaemic stem cells …

Despite considerable progress has been achieved in the treatment of acute myeloid
leukemia over the past decades, relapse remains a major problem. Novel therapeutic …

Natural killer (NK) cells are large granular lymphocytes involved in our defense against
certain virus-infected and malignant cells. In contrast to T cells, NK cells elicit rapid anti …

The emergence of immunotherapy for cancer treatment bears considerable clinical promise.
Nevertheless, many patients remain unresponsive, acquire resistance, or suffer dose …

The remarkable progress in engineering and clinical development of therapeutic antibodies
in the last 40 years, after the seminal work by Köhler and Milstein, has led to the approval by …

Natural killer (NK) cells are important innate cytotoxic lymphocytes with a rapid and efficient
capacity to recognize and kill tumor cells. In recent years, adoptive transfer of autologous-or …

In the last two decades, monoclonal antibodies have revolutionized the therapy of cancer
patients. Although antibody therapy has continuously been improved, still a significant …

Natural killer (NK) lymphocytes are an integral component of the innate immune system and
represent important effector cells in cancer immunotherapy, particularly in the control of …